<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39314485</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Differential Immunoregulation by Human Surfactant Protein A Variants Determines Severity of SARS-CoV-2-induced Lung Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2024.09.11.612497</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2024.09.11.612497</ELocationID><Abstract><AbstractText>COVID-19 remains a significant threat to public health globally. Infection in some susceptible individuals causes life-threatening acute lung injury (ALI/ARDS) and/or death. Human surfactant protein A (SP-A) is a C-type lectin expressed in the lung and other mucosal tissues, and it plays a critical role in host defense against various pathogens. The human SP-A genes ( <i>SFTPA1</i> and <i>SFTPA2</i> ) are highly polymorphic and comprise several common genetic variants, i.e., SP-A1 (variants 6A <sup>2</sup> , 6A <sup>4</sup> ) and SP-A2 (variants 1A <sup>0</sup> , 1A <sup>3</sup> ). Here, we elucidated the differential antiviral and immunoregulatory roles of SP-A variants in response to SARS-CoV-2 infection <i>in vivo</i> . Six genetically-modified mouse lines, expressing both hACE2 (SARS-CoV-2 receptor) and individual SP-A variants: (hACE2/6A <sup>2</sup> (6A <sup>2</sup> ), hACE2/6A <sup>4</sup> (6A <sup>4</sup> ), hACE2/1A <sup>0</sup> (1A <sup>0</sup> ), and hACE2/1A <sup>3</sup> (1A <sup>3</sup> ), one SP-A knockout (hACE2/SP-A KO (KO) and one hACE2/mouse SP-A (K18) mice, were challenged intranasally with 10 <sup>3</sup> PFU SARS-CoV-2 or saline (Sham). Infected KO and 1A <sup>0</sup> mice had more weight loss and mortality compared to other mouse lines. Relative to other infected mouse lines, a more severe ALI was observed in KO, 1A <sup>0</sup> , and 6A <sup>2</sup> mice. Reduced viral titers were generally observed in the lungs of infected SP-A mice relative to KO mice. Transcriptomic analysis revealed an upregulation in genes that play central roles in immune responses such as <i>MyD88</i> , <i>Stat3</i> , <i>IL-18</i> , and <i>Jak2</i> in the lungs of KO and 1A <sup>0</sup> mice. However, <i>Mapk1</i> was significantly downregulated in 6A <sup>2</sup> versus 1A <sup>0</sup> mice. Analysis of biological pathways identified those involved in lung host defense and innate immunity, including pathogen-induced cytokine, NOD1/2, and Trem1 signaling pathways. Consistent with the transcriptomic data, levels of cytokines and chemokines such as G-CSF, IL-6 and IL-1Î² were comparatively higher in the lungs and sera of KO and 1A <sup>0</sup> mice with the highest mortality rate. These findings demonstrate that human SP-A variants differentially modulate SARS-CoV-2-induced lung injury and disease severity by differentially inhibiting viral infectivity and regulating immune-related gene expressions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>Ikechukwu B</ForeName><Initials>IB</Initials></Author><Author ValidYN="Y"><LastName>Lawal</LastName><ForeName>Akinkunmi O</ForeName><Initials>AO</Initials></Author><Author ValidYN="Y"><LastName>Mahmoud</LastName><ForeName>Salma S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Kopsack</LastName><ForeName>Emerson M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Erin S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Qinghe</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Hongkuan</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Massa</LastName><ForeName>Paul T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Thangamani</LastName><ForeName>Saravanan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4269-5993</Identifier></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Hongpeng</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guirong</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>4</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39314485</ArticleId><ArticleId IdType="pmc">PMC11418998</ArticleId><ArticleId IdType="doi">10.1101/2024.09.11.612497</ArticleId><ArticleId IdType="pii">2024.09.11.612497</ArticleId></ArticleIdList></PubmedData></PubmedArticle>